Company Overview

Encision Inc. (formerly traded as ECIA) was a U.S.-based medical device company focused on improving patient safety during minimally invasive and electrosurgical procedures. The company operated within the medical device and surgical technology industries, with its core offering centered on proprietary Active Electrode Monitoring (AEM) technology designed to reduce the risk of unintended burns during laparoscopic and other minimally invasive surgeries.

Encision’s primary revenue driver was the sale of AEM-enabled disposable and reusable surgical instruments and related monitoring systems, sold primarily to hospitals and surgical centers. The company served surgeons and healthcare systems seeking enhanced safety solutions in electrosurgery, positioning itself as a niche provider with a differentiated safety-focused technology. Encision was founded in the early 1990s and developed its technology over several decades before being acquired in 2018, at which point it ceased operating as an independent public company.

Business Operations

Encision generated revenue through the development, manufacturing, and commercialization of electrosurgical instruments incorporating its AEM technology, which continuously monitored electrical current to detect insulation failures and stray energy. Its business model combined capital equipment sales (monitoring units) with recurring revenue from disposable surgical instruments compatible with the AEM system.

Operations were primarily U.S.-based, with manufacturing and R&D activities historically centered domestically, while international sales were supported through distribution partners. Encision did not publicly disclose multiple operating segments, and available filings describe the business as operating as a single reportable segment. Information regarding wholly owned subsidiaries or joint ventures is limited in public disclosures; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Encision focused on expanding adoption of its AEM technology by increasing surgeon awareness, securing hospital system approvals, and integrating its technology into standard laparoscopic workflows. Growth initiatives emphasized clinical education, incremental product enhancements, and broader distribution rather than diversification into unrelated medical device categories.

The most significant strategic event in the company’s history was its acquisition by Bovie Medical Corporation in 2018, a publicly traded electrosurgical device company. This transaction integrated Encision’s technology into a larger electrosurgical product portfolio and provided greater scale for commercialization. Beyond this acquisition, there is no verified evidence of Encision holding notable equity investments or operating a portfolio of subsidiaries; data inconclusive based on available public sources.

Geographic Footprint

Encision was headquartered in the United States, with historical operations based in Colorado. Its primary market was North America, where the majority of revenue was generated through direct sales and distributor relationships with hospitals and surgical centers.

Internationally, Encision maintained a limited presence through third-party distributors in select markets in Europe and other regions, though international revenue represented a smaller portion of total sales. The company did not maintain significant overseas manufacturing facilities or regional headquarters outside the U.S., based on publicly available filings.

Leadership & Governance

Encision was founded by medical device entrepreneurs focused on surgical safety innovation, though detailed founder attribution varies across public records. Prior to its acquisition, the company was led by an executive team with experience in medical device commercialization and regulatory compliance.

Key executives reported in public disclosures included:

• John R. Francis – President and Chief Executive Officer
• William E. McCarthy – Chief Financial Officer
• Kirk M. Smith – Vice President of Sales

Leadership emphasized a strategy centered on patient safety, clinical validation, and disciplined commercialization within a narrowly defined electrosurgical niche. Governance followed standard public company practices until the company was acquired and delisted; additional details on board composition are limited, and data inconclusive based on available public sources.